FDA Approves AstraZeneca's Baxfendy for Refractory Hypertension

By FieldPulse Staff · May 22, 2026

Tags: launch, strategy

AstraZeneca secures FDA approval for Baxfendy (baxdrostat), a new once-daily treatment for refractory hypertension.

The FDA has officially approved Baxfendy (baxdrostat) for the treatment of hypertension in patients who have not achieved adequate blood pressure control on three or more antihypertensive medications.

This approval, granted on May 15, 2026, marks a significant milestone for AstraZeneca's cardiovascular portfolio.

Baxfendy is a once-daily, highly selective aldosterone synthase inhibitor (ASI).

In Phase III trials, it demonstrated a statistically significant reduction in systolic blood pressure compared to placebo.

For AZ reps, this launch represents a major opportunity in the primary care and cardiology space, though the competitive landscape remains crowded.

"This approval provides a much-needed option for patients struggling with resistant hypertension," said an industry analyst.

"The challenge for the field force will be navigating the payer landscape and ensuring Baxfendy is positioned correctly against established generics and newer branded entries.".